HuffPost Canada closed in 2021 and this site is maintained as an online archive. If you have questions or concerns, please check our FAQ or contact support@huffpost.com.

pharmaceutical companies

We have heard a lot about legalization, and right now everyone is talking about the regulations that will go along with that legalization, but it would be prudent to remember the mandate of the government: Legalize, Regulate, and Restrict Access to minor of cannabis products.
It's natural for any industry to undergo changes, but few industries have experienced as many rapid changes as the pharmaceutical and health care ones. To remain relevant among these digitally wired consumers, big pharmaceutical companies have adjusted, making visible efforts to grab the audience's attention through web and mobile presence.
I understand people's anger toward anti-vaccination and other "non-scientific" belief systems. But let's use science to help solve the problem, and not let our emotions get the better of us. Rather than type insults on Twitter, our time might be best spent advocating for more research grant money to help better understand this important issue.
A conference was held a few weeks ago in Ottawa to discuss yet again the adoption of a pan-Canadian government-run drug insurance plan that would cover prescription drug costs for the entire population. Such a program would instead risk increasing the burden currently weighing down public finances. Such a plan would not only entail extra costs for taxpayers, but would do nothing to change governments' current propensity to restrict and delay access to new drugs. Foreign experience can teach us much about the dangers of adopting a monopolistic drug insurance system in Canada.
In Canada the drug industry spends roughly $3 billion per year marketing its products, two-thirds of which goes towards the salaries of the sales reps who visit our physicians regularly, and the drug samples they use to enhance their one-on-one learning sessions.